Re: Competition from Constellation

...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Reply New Message

Prev Message Back To Forum Threaded View Next Message

BearDownAZ

Rank: President [?]

Points: 25003 [?]

Votes: 68 Score: 4.5 [?]

Your Vote:

Please Log In to Vote

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

Re: Competition from Constellation

in response to

Competition from Constellation

masila

posted on Dec 13, 2017 04:21PM

Thanks for sharing Masila. Just to clarify, this compound in question from Constellation is not their BET inhibitor CPI-0610. It is their EZH2 inhibitor CPI-1205. EZH2 is a histone methyltransferase, so it is in the "writer" category in the simplified "reader, writer, eraser" analogy of epigenetics. So although this CPI-1205 compound introduces competition in the epigenetic drug/metastatic castrate resistant prostate cancer space, it is not introducing another BET inhibitor competitor.